A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. METHODS: We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer. RESULTS: During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. CONCLUSIONS: The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [16]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Self-citationKyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Self-citationMonoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Self-citationFrequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population
AXELSSON, U., BACHMANN, R., & HÄLLÉN, J. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb05453.x · Cited by 436
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
KYLE, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 338
Self-citationThe Analysis of Mortality by the Subject-Years Method
Berry, G. (1983) · Biometrics · doi:10.2307/2530817 · Cited by 278
Research works printed but not linked: 4
- Hallen J, 1966, Acta Med Scand Suppl, 462, 1
- Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology. 5th ed. Washington, D.C.: ASM Press, 1997:156-76.
- Kyle RA, 1999, Blood, 94, 537a
- Fonseca R, 1999, Blood, 94, 663a
Cited by
Items 801–900 of 1,000
Iwanaga, M., & Tomonaga, M. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.12.010 · Cited by 9
Familial Multiple Myeloma: Report on Two Families and Discussion of Screening Options
Gerkes, E. H., de Jong, M. M., Sijmons, R. H., & Vellenga, E. (2007) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-5-2-72 · Cited by 9
“The quality of life of patients can be improved by averting these events and the cost of long-term dialysis or surgical intervention for skeletal complications would be reduced [27].”
BackgroundHIV Infection Masquerading as Monoclonal Gammopathy of Undetermined Significance
Lu, C. M., Dezube, B. J., & Pantanowitz, L. (2003) · New England Journal of Medicine · doi:10.1056/nejm200309183491222 · Cited by 9
The Current Status and Future of Multiple Myeloma in the Clinic
Jagannath, S., Kyle, R. A., Palumbo, A. P., Siegel, D. S. D., Cunningham, S. A., & Berenson, J. R. (2009) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clm.2010.n.005 · Cited by 10
Self-citationOn the “Significance” of Monoclonal Gammopathy of Undetermined Significance
Bladé, J. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.855 · Cited by 9
Diagnostic evaluation of monoclonal gammopathy of undetermined significance
Rajan, A. M., & Rajkumar, S. V. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12198 · Cited by 11
“Monoclonal gammopathy of undetermined significance (MGUS) is a common premalignant plasma cell proliferative disorder present in over 3% of the general population 50 yrs and older (1, 2).”
BackgroundSelf-citationPlasma Cell Neoplasms, Their Precursor States, and Their Prediction of Organ Damage
Comenzo, R. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2892 · Cited by 9
“Monoclonal gammopathies are common, but the challenge is to determine whether they are passengers that are linked to putative immune or autoimmune dysregulation, or true drivers of disease or, as sometime happens, both.(13,14) The symptoms of”
BackgroundZuern, K., Hielscher, T., Werly, A., Breitkreutz, I., Sauer, S., Raab, M. S., Müller‐Tidow, C., Goldschmidt, H., & Mai, E. K. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01126-3 · Cited by 9
Quartuccio, L., Manfrè, V., Treppo, E., Perrotta, F. M., Ragab, G., Goules, A. V., & Lubrano, E. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103895 · Cited by 9
Management of monoclonal gammopathy of renal significance: treatment standard
Jaturapisanukul, S., Nasr, S. H., & Leung, N. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf254 · Cited by 9
Kidney Biopsy in Patients With Monoclonal Gammopathy: A Multicenter Retrospective Cohort Study
Nie, S., Wang, M., Wan, Q., Kong, Y., Ou, J., Jia, N., Zhang, X., Luo, F., Liu, X., Wang, L., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.687149 · Cited by 8
“Monoclonal gammopathies are a group of disorders ranging from non-malignant small clonal proliferations to malignant neoplasms of plasma cells or B-lymphocytes (3, 4).”
BackgroundMultiple Myeloma: Risk Factors, Pathogenesis and Relationship with Anti-myeloma Therapies
Nwabuko, O. C. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2022.00059 · Cited by 9
Multiple myeloma and its rare paraneoplastic manifestations simmering under the surface
Baloch, S. S., Khan, S. R., Tariq, M. Z., Wasio, A., Ali, A. A., Shahzadi, M., Moosajee, M., Anwar, S., Raza, A., & Shahab Uddin, M. S. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154689 · Cited by 9
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS
Bravo‐Pérez, C., & Gurnari, C. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.004 · Cited by 8
Moreno, D. F., Jiménez, C., Escalante, F., Askari, E., Castellanos‐Alonso, M., Arnao, M., Heredia, Á., Canales, M. Á., Alcalá, M., Bermúdez, A., et al. (2024) · HemaSphere · doi:10.1002/hem3.70029 · Cited by 8
“The diagnostic criteria followed local institutional protocols of each center and included the Mayo Clinic 16,17 or the International Consensus criteria.”
BackgroundMethodRueda, L. Y. M., Wang, H., Akagi, K., Dang, M., Vora, A. U., Qin, L., Lee, H. C., Patel, K. K., Lin, P., Mery, D. E., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101925 · Cited by 9
Multiples Myelom: Aktuelle Empfehlungen für die Bildgebung
Hillengaß, J., & Delorme, S. (2012) · Der Radiologe · doi:10.1007/s00117-011-2257-0 · Cited by 8
MyelomA Genetics International Consortium
Morgan, G. J., Johnsen, H. E., Goldschmidt, H., Palumbo, A. P., Cavo, M., Sonneveld, P., Miguel, J. F. S., Chim, C. S., Browne, P., Einsele, H., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.639881 · Cited by 8
Telomere dynamics in adult hematological malignancies
Olbertová, H., Plevová, K., Stránská, K., & Pospíšilová, Š. (2019) · Biomedical Papers · doi:10.5507/bp.2018.084 · Cited by 8
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00104-1 · Cited by 10
Self-citationRaimondi, V., Iannozzi, N. T., Burroughs-Garcìa, J., Toscani, D., Storti, P., & Giuliani, N. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00095 · Cited by 8
“The MGUS clone is subsequently affected by secondary abnormalities that may or may not lead to the transition to the MM [7].”
BackgroundInfluentialPlasma Cell Myeloma/Multiple Myeloma
Bahk, W.-J. (2023) · Springer eBooks · doi:10.1007/978-981-99-5498-8_5 · Cited by 8
Synergy of two human endogenous retroviruses in multiple myeloma
Schmidt, K. L. M., Vangsted, A. J., Hansen, B. D., Vogel, U. B., Hermansen, E., Jensen, S. B., Laska, M. J., & Nexø, B. A. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.06.014 · Cited by 9
Hamidou, M. A., Belizna, C. C., Wiertlewski, S., AUDRAIN, M. A. P., Biron, C., Grolleau, J., & Mussini, J. M. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.12.008 · Cited by 8
HIV, EBV, and monoclonal gammopathy
Mailankody, S., & Landgren, O. (2013) · Blood · doi:10.1182/blood-2013-08-522508 · Cited by 8
Chang, C.-M., Hwang, W.-L., Hsieh, Z. Y., Wang, R., & Teng, C. J. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0880-x · Cited by 8
“As a pre-malignant plasma cell proliferative disorder, MGUS has a lifelong risk of progression to multiple myeloma [1].”
BackgroundMonoclonal Gammopathy of Undetermined Significance
Go, R. S., Heien, H. C., Sangaralingham, L. R., Habermann, E. B., & Shah, N. D. (2017) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2017.06.002 · Cited by 9
“Although MGUS is generally considered a benign condition with a low rate of transformation to lymphoplasmacytic malignancies (LPMs), the risk continues indefinitely.(2) Therefore, patients are followed up regularly to anticipate such an event at an early stage with the hope of preventing serious cancer-related complic…”
BackgroundChiang, H. H., Wieland, R. S., Rogers, T. S., Gibson, P. C., Atweh, G. F., & McCormick, G. J. (2017) · Medicine · doi:10.1097/md.0000000000008649 · Cited by 8
“0000000000008649 1 proportion do progress to premalignant andmalignant monoclonal gammopathies such as smouldering multiple myeloma, multiple myeloma, Waldenström’s macroglobinemia, primary amyloidosis, B-cell lymphoma, or chronic lymphocytic leukemia.([2]) Corneal deposits have long been associated with monoclonal ga…”
BackgroundTanaka, T., Fuga, M., Teshigawara, A., Hasegawa, Y., Nishiwaki, K., Murayama, Y., & Yokoo, H. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.07.212 · Cited by 8
Monoclonal Gammopathy and Smoldering Multiple Myeloma: Diagnosis, Staging, Prognosis, Management
Hillengaß, J., Moehler, T. M., & Hundemer, M. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_6 · Cited by 9
“found that patients with a paraprotein level of 25 g/dl or higher had a risk of 49% to develop multiple myeloma or related disorder (Kyle et al. 2002).”
BackgroundGalioto, A., Morando, F., Rosi, S., Schipilliti, M., Fasolato, S., Magrin, M., Frigo, A. C., Adami, F., Cavallin, M., Zanus, G., et al. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01362.x · Cited by 8
“Since patients with MGUS progress to myeloma multiple or B malignant lymphoproliferative disorders at a rate of 1% per year, approximately, it is not considered as ‘benign’ [3].”
BackgroundOnwah, A., Adeyemo, T. A., Adediran, A., John‐Olabode, S., & Akanmu, S. A. (2012) · BMC Blood Disorders · doi:10.1186/1471-2326-12-7 · Cited by 8
“Background Monoclonal Gammopathy of Undetermined Significance (MGUS) is the most common of a spectrum of diseases called plasma cell dyscrasias [1,2], which are a heterogeneous group of diseases characterized by the expansion of a clone of bone marrow plasma cells that produce monoclonal immunoglobulin (Ig).”
Prevalence of paraproteinaemia in older Australians
Suan, D., Hughan, M., Bates, S., Rochtchina, E., Empson, M. B., Mitchell, P. B., & Fulcher, D. A. (2011) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02568.x · Cited by 8
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00101-8 · Cited by 8
Self-citationWaldenström macroglobulinemia: biology, genetics, and therapy
Ansell, S. M., & Paludo, J. (2016) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s84157 · Cited by 8
“In patients with a history of IgM monoclonal gammopathy of undetermined significance (MGUS), a known precursor of WM, the risk of WM is increased by 46-fold.(16) IgM MGUS patients carrying the MYD88 L265P mutation have higher risk of progressing to WM than those with wild-type MYD88 (odds ratio 4.”
BackgroundRosai–Dorfman disease simulating metastatic breast carcinoma
Yu, K. K., Briones, N. F., Chan, M. P., Ahmed, A. Z., & Stevens, E. L. (2019) · JAAD Case Reports · doi:10.1016/j.jdcr.2019.02.021 · Cited by 8
Hannich, M. J., Konen, F. F., Gag, K., Alkhayer, A., Türker, S. N., Budde, K., Nauck, M., Wurster, U., Dressel, A., Skripuletz, T., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1468 · Cited by 7
Gort-Freitas, N. A., Moscvin, M., Vià, M. D., Lazzaroni, F., Nevone, A., Sadigh, S., Boullt, S., Evans, B., Chen, T., Karagiannis, T. T., et al. (2025) · Blood · doi:10.1182/blood.2024024719 · Cited by 7
Systemic and localised light-chain amyloidosis: two diseases
Röcken, C. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00071-x · Cited by 7
Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis
Muchtar, E., Magen, H., Itchaki, G., Cohen, A., Rosenfeld, R., Shochat, T., Kornowski, R., Iakobishvili, Z., & Raanani, P. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.11.013 · Cited by 8
Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders
Manier, S., Salem, K. Z., Liu, D., & Ghobrial, I. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159010 · Cited by 8
Paraneoplastic Sarcoidosis in Multiple Myeloma
Kusaba, K., Kojima, K., Naito, S., Taba, M., Kai, K., Ureshino, H., Nishida, Y., & Kimura, S. H. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.8331 · Cited by 7
“Considering that almost all patients with myeloma evolve from a long-lasting (median, 10 years) and asymptomatic premalignant stage termed monoclonal gammopathy of undetermined significance (10), myeloma-associated sarcoidosis could represent a specific disease entity caused by an abnormal immune response to myeloma c…”
BackgroundYu, C. Y., Xiang, S., Huang, Z., Johnson, T. S., Zhan, X., Han, Z., Zaid, M. I. A., & Huang, K. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00468 · Cited by 7
Characterization of the role of Samsn1 loss in multiple myeloma development
Friend, N., Hewett, D. R., Panagopoulos, V., Noll, J. E., Vandyke, K., Mrozik, K. M., Fitter, S., & Zannettino, A. C. W. (2020) · FASEB BioAdvances · doi:10.1096/fba.2020-00027 · Cited by 8
The clinical and pathological features of plasma cell myeloma post solid organ transplantation
Ofori, K., Soderquist, C. R., Murty, V. V. V. S., Park, D., Vlad, G., Leeman‐Neill, R. J., Lentzsch, S., Alobeid, B., & Bhagat, G. (2020) · American Journal of Hematology · doi:10.1002/ajh.25988 · Cited by 7
“Moreover, spontaneous resolution of MGUS has been reported in 21%-37% of solid organ allograft recipients, compared to 2% of non-transplant patients.(56,57,61) This difference might relate to distinct (non-neoplastic) etiology of the majority of PT-MGUS cases, i.”
BackgroundPET Imaging for Hematologic Malignancies
Hughes, N., & Jacene, H. A. (2021) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2021.05.003 · Cited by 7
Bai, Z., Hu, C., Zhong, J., & Dong, L. (2022) · Modern Rheumatology · doi:10.1093/mr/roac066 · Cited by 7
Bradey, A. L., Fitter, S., Duggan, J., Wilczek, V. J., Williams, C. M. D., Cheney, E. A., Noll, J. E., Tangseefa, P., Panagopoulos, V., & Zannettino, A. C. W. (2022) · Scientific Reports · doi:10.1038/s41598-022-17403-9 · Cited by 8
A novel glycolysis-related gene signature for predicting the prognosis of multiple myeloma
Zhang, B., Wang, Q., Lin, Z., Zheng, Z., Zhou, S., Zhang, T., Zheng, D., Chen, Z., Zheng, S., Zhang, Y., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1198949 · Cited by 8
“MM is a highly heterogenous disease, that exits on a continuous disease spectrum ranging from precancerous states monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) driven by the accumulating genetic changes and immune escape (Kyle et al., 2002; Kyle et al., 2007; Landgren…”
BackgroundRegression of smoldering myeloma with treatment of Gaucher disease
Barley, K. M., Parekh, A., Salam, S. P., Mendu, D. R., Shukla, R. P., Vatti, D., Verina, D., Stauffer, C., Salib, C., Jamal, S. M. E., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012304 · Cited by 7
Li, Y., Hsu, S. H., Wang, R., Theprungsirikul, P. P., Neparidze, N., Chang, S., & Wang, S. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.12.006 · Cited by 11
Incidental finding of monoclonal gammopathy in blood donors: a follow-up study.
Raja, M. L., Barcobello, M., Bet, N., Dolfini, P., Florean, M., Tomasella, F., Angelis, V. D., & Mascaretti, L. G. (2012) · Europe PMC (PubMed Central) · doi:10.2450/2012.0083-11 · Cited by 17
Incidence of gammopathies in long‐term plasmapheresis donors at Canadian Blood Services
Palmer, D. S., Scalia, V., O'Toole, J., Welch, C., Yi, Q., & Goldman, M. (2015) · Transfusion · doi:10.1111/trf.12991 · Cited by 7
“In agreement with other reports, we found an increased incidence of gammopathies with increasing age.(7,11,14,27-31) While there is no evidence that continued donation of plasma increases the potential risk of developing a Mc gammopathy in donors or in patients receiving plasma transfusions from such donors,(7,9,11,12…”
Result“Idiopathic Bence-Jones proteinuria”: a new characterization of an old entity
Mian, M., Franz, I., Wasle, I., Herold, M., Griesmacher, A., Prokop, W., Cortelazzo, S., Gastl, G. A., Willenbacher, W., Gunsilius, E., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1739-8 · Cited by 7
“defined MGUS with a bone marrow plasma cell count of ≤10% and we applied the same criteria [10].”
MethodLee, Y.-G., Bang, S., Lee, J., Kim, J. W., Lee, K., Kim, J. H., Song, J. H., Kim, T.-H., Kim, K. W., & Lee, J.-S. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2013.262 · Cited by 7
Viral co-infections and paraproteins in HIV: effect on development of hematological malignancies
Jou, E., Gligich, O., Chan, A. C. Y., Mohan, D., Felsen, U. R., Ayyappan, S. R., Billett, H. H., Hui, E. P., Chan, A. T. �., & Raghupathy, R. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2588-z · Cited by 7
Kuwabara, C., Sakuma, Y., Kume, A., Tamura, Y., Shimizu, R., Iwai, R., Ishii, A., & Tanaka, H. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2555-7 · Cited by 7
Li, Y., & Lin, Y. (2019) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2019.2018.0238 · Cited by 7
Identifying monoclonal gammopathy of undetermined significance in electronic health data
Epstein, M. M., Saphirak, C., Zhou, Y., Leblanc, C., Rosmarin, A. G., Ash, A. S., Singh, S., Fisher, K. A., Birmann, B. M., & Gurwitz, J. H. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4912 · Cited by 7
Liang, D., Liu, J., Liang, S., Xu, F., Cheng, Z., Huang, X., Zeng, C., & Liu, Z. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00817-x · Cited by 7
Clinicopathological characteristics of patients with paraproteinemia and renal damage
Tang, X., Wan, F., Yü, J., Li, X., Yang, R., & Zhu, B. (2021) · European journal of medical research · doi:10.1186/s40001-021-00538-2 · Cited by 8
Learning to Detect Monoclonal Protein in Electrophoresis Images
Li, H., Racine‐Brzostek, S., Xi, N., Luo, J., Zhao, Z., & Yuan, J. (2021) · IEEE International Conference on Visual Communications and Image Processing (VCIP) · doi:10.1109/vcip53242.2021.9675332 · Cited by 7
“Lymphoproliferative processes and monoclonal gammopathies (MGs) are both plasma cell disorders(1), which often result in end-organ symptoms including renal insufficiency, osteolytic bone lesion and anemia(2).”
BackgroundA descriptive study of plasma cell dyscrasias in Egyptian population
Kassem, N. M. A., Zawam, H. E., Kassem, H. A., Nahas, T. I. H. E., Husseiny, N. M. E., & Azeeim, H. A. E. (2013) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2013.09.002 · Cited by 7
Monoclonal gammopathy of undetermined significance maculopathy
Saffra, N. A., Rakhamimov, A., Solomon, W. B., & Scheers-Masters, J. (2013) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2013.07.018 · Cited by 7
“The prognosis for MGUS in the geriatric population is variable, as there is a risk for progression to multiple myeloma or other lymphoproliferative disorders of 1% per year.(1) The occurrence of MGUS in people younger than 40 years is rare, so much so that exact data regarding the incidence and prognosis in this age g…”
BackgroundIndividualizing Therapy Using Molecular Markers in Multiple Myeloma
Bergsagel, P. L. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.019 · Cited by 8
Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults
Guerard, E. J., & Tuchman, S. A. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.08.012 · Cited by 7
Serum Free Light Chain Analysis
Selvaratnam, R., Cao, J., & Karger, A. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-10918-3_2 · Cited by 7
Sabatino, R., Perrone, A., Cuomo, M., Liotti, S., Barchiesi, V., Cantile, M., & Cavalcanti, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040804 · Cited by 8
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Sandecká, V., Pour, L., Adam, Z., Krejčí, M., Štork, M., Ševčíková, S., & Král, Z. (2018) · Klinicka onkologie · doi:10.14735/amko2018270 · Cited by 9
Epidemiology of Multiple Myeloma
Ríos, R., Rodríguez, D. S., Chang-Chan, D. Y.-L., & Sánchez, M.-J. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.75396 · Cited by 7
Morgan, G. J., Linet, M. S., & Rabkin, C. S. (2006) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195149616.003.0027 · Cited by 7
Waldenstrom's macroglobulinemia
Ansell, S. M., Hodge, L. S., & Hayman, S. R. (2002) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_24 · Cited by 7
Acromegaly Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS)
Kanazawa, I., Yamaguchi, T., Yamane, Y., MURAKAMI, N., Kato, Y., & Sugimoto, T. (2006) · Endocrine Journal · doi:10.1507/endocrj.k05-173 · Cited by 7
Splenic Rupture following Colonoscopy in a Hemodialysis Patient
Zerbi, S., Crippa, S., Bella, C. D., Nobili, P., Bonforte, G., & Scanziani, R. (2006) · The International Journal of Artificial Organs · doi:10.1177/039139880602900312 · Cited by 7
Nephrology Quiz and Questionnaire
Glassock, R. J., Bargman, J. M., Palmer, B. F., Samaniego, M., & Fervenza, F. C. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00540110 · Cited by 7
Alejo, E., González‐Calle, V., Blázquez, P. M., Puertas, B., Agulló, C., Rey-Búa, B., Gutierrez, N. C., Puig, N., & Mateos, M. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01371-0 · Cited by 7
Yadav, R., Chaudary, J. K., Bisht, K., Dhamija, P., Chaudhary, P. K., Nath, U. K., & Jain, N. K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152390 · Cited by 7
Németh, O., Tapasztó, B., Tar, S., Szabó, V., Nagy, Z. Z., Tóth, J., Hamed, A., Mikala, G., & Szentmáry, N. (2018) · Orvosi Hetilap · doi:10.1556/650.2018.31196 · Cited by 6
“[17] Kyle RA, Therneau TM, Rajkumar SV, et al.”
BackgroundLAMP5 may promote MM progression by activating p38
Chen, Y., & Ma, T. (2023) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611083 · Cited by 7
“MGUS is present in approximately 2% of people over 50 years of age, and MGUS progresses to MM at a rate of 1% per year (23, 24).”
BackgroundRelationship among three common hematological premalignant conditions
Boddicker, N. J., Parikh, S. A., Norman, A. D., Rabe, K. G., Griffin, R., Call, T. G., Robinson, D. P., Olson, J. E., Dispenzieri, A. A., Rajkumar, S. V., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01914-z · Cited by 6
Self-citationHe, H., Wang, Z., Xu, J., Liu, Y., Shao, Y., Hou, Y., Gu, J., Hu, R., & Xing, G. (2024) · Scientific Reports · doi:10.1038/s41598-024-58467-z · Cited by 6
Bergón, E., Miravalles, E., Bergón, E., Miranda, I., & Bergón, M. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2005.004 · Cited by 6
“Some authors accurately question the need for bone marrow examination in asymptomatic patients unless the M-protein value is )2 g/dL (4, 9).”
BackgroundCD4+CD25+ cells in multiple myeloma related renal impairment
Huang, H., Luo, Y., Liang, Y., Long, X., Peng, Y., Liu, Z., Wen, X., Meng, J., Ru, T., Bai, C., et al. (2015) · Scientific Reports · doi:10.1038/srep16565 · Cited by 6
My Patient with Monoclonal Gammopathy of Undetermined Significance has a Kidney Problem
Leung, N. (2017) · Journal of Onco-Nephrology · doi:10.5301/jo-n.5000005 · Cited by 6
“Long-term follow-up of patients with MGUS reveals a constant rate of malignant transformation that is unabated even after 30 years (1).”
BackgroundInfluentialAnalysis of interval-censored competing risks data under missing causes
Mitra, D., Das, U., & Das, K. (2019) · Journal of Applied Statistics · doi:10.1080/02664763.2019.1642309 · Cited by 6
Global DNA methylation and increased DNMT3A expression in multiple myeloma patients
Luzna, P., Drozdková, D. W., Flodrová, P., Ondrušková, K., Überall, I., Minařík, J., Kolář, Z., & Trtková, K. S. (2022) · Biomedical Papers · doi:10.5507/bp.2022.006 · Cited by 6
Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives
Barreto, I. V., Machado, C. B., Almeida, D. B., Pessoa, F. M. C. D. P., Gadelha, R. B., Pantoja, L. D. C., Oliveira, D. D. S., Ribeiro, R. M., Lopes, G. S., de Moraes, M. O., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091784 · Cited by 7
Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review
Ismail, N. H., Mussa, A., Al‐Khreisat, M. J., Yusoff, S. M., Husin, A., & Johan, M. F. (2023) · Diagnostics · doi:10.3390/diagnostics13142328 · Cited by 6
Jou, E., Gligich, O., Chan, A. C. Y., Mohan, D., Felsen, U. R., Ayyappan, S. R., Billett, H. H., Hui, E. P., Chan, A. T. �., & Raghupathy, R. (2015) · Hematological Oncology · doi:10.1002/hon.2247 · Cited by 6
“Monoclonal gammopathy of unknown significance (MGUS) is a plasma cell dyscrasia that occurs in 1 to 3% of people over the age of 50 years and progresses to various hematological malignancies (HM) such as lymphoma, myeloma and AL amyloidosis at the rate of about 1% per year [1].”
BackgroundTete, S. M., Horst, G., Wilting, K. R., Klijn, M. A., Westra, J., de Haan, A., Huckriede, A. L. W., Kluin‐Nelemans, H. C., Sahota, S. S., Bijl, M., et al. (2013) · Hematology and Leukemia · doi:10.7243/2052-434x-1-3 · Cited by 7
Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias
Özsan, G. H., & Dispenzieri, A. A. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.80 · Cited by 6
Immunoglobulines monoclonales : méthodes diagnostiques en 2011
Beauvillain, C., Jeannin, P., Rénier, G., & Chevailler, A. (2011) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(11)71005-x · Cited by 6
Santiago, T. M. G., Lehman, J. S., Buonaccorsi, J. N., Kalaaji, A. N., & Wieland, C. N. (2015) · Journal of Cutaneous Pathology · doi:10.1111/cup.12657 · Cited by 6
Al‐Ammari, M., & Adam, S. S. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-217697 · Cited by 6
Current options to manage Waldenström’s macroglobulinemia
Benevolo, G., Nicolosi, M., Santambrogio, E., & Vitolo, U. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1339596 · Cited by 6
“The preexisting IgM monoclonal gammopathy of unknown significance (IgM-MGUS) is themost relevant risk factor for development of WM [12].”
BackgroundMonoclonal gammopathies: Electronic subspecialty consultation
Burwick, N. R., Stein, J. N., Garcia, D. A., Broudy, V. C., & Richard, R. E. (2017) · European Journal Of Haematology · doi:10.1111/ejh.13019 · Cited by 6
Diagnosis and Staging of Multiple Myeloma and Related Disorders
Rajkumar, S. V., Fonseca, R., & Miguel, J. F. S. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_2 · Cited by 7
Self-citationAbnormal Plasma Cell Disorders in Refinery Waste Workers
Ledda, C., Loreto, C., Filetti, V., Matera, S., Vitale, E., Bracci, M., & Rapisarda, V. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080221 · Cited by 6
“Long-term studies on MGUS cases verified an average risk of 1% per year of developing multiple myeloma (MM) or a correlated lymphoproliferative malignancy [9,10].”
BackgroundYu, P. L. I., Wang, R. R., Johnston, G., Wang, Y., Tammur, P., Tamm, A., Punab, M., Pozzo, A. R., & Mai, S. (2019) · Cells · doi:10.3390/cells8070723 · Cited by 7
Multiple Myeloma and Change of ABO Blood Group Type: A Case Report
Waleed, M. S., & Sadiq, W. (2020) · Cureus · doi:10.7759/cureus.10654 · Cited by 6
“Three percent of the population above the age of 50 have monoclonal gammopathy of undetermined significance (MGUS) that can further turn into a malignancy at a rate of approximately 1% per year [3,4].”
Background
Metadata
- Authors
- Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-21
- Volume
- 346
- Issue
- 8
- Pages
- 564-569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2000655497
- Cited by
- 1,475
- References
- 17
- Citations by year
- 2026: 32 · 2025: 51 · 2024: 66 · 2023: 48 · 2022: 62 · 2021: 65 · 2020: 66 · 2019: 56 · 2018: 67 · 2017: 62 · 2016: 59 · 2015: 63 · 2014: 74 · 2013: 87 · 2012: 63
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA6 2242, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, prognosis, plasma cell neoplasms, AL amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, plasmacytoma, smoldering multiple myeloma, bone marrow plasma cells, risk prediction
- MeSH terms
- Adult, Aged, Amyloidosis, Follow-Up Studies, Humans, Leukemia, Lymphoid, Lymphoma, Waldenstrom Macroglobulinemia, Middle Aged, Multiple Myeloma, Paraproteinemias, Probability, Prognosis, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.